BioMarin Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 700.26 M

BioMarin Pharmaceutical Inc. Operating Cash Flow is USD 700.26 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 149.95% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • BioMarin Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 280.16 M, a 90.07% change year over year.
  • BioMarin Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 147.40 M, a 1.24% change year over year.
  • BioMarin Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 145.59 M, a -31.99% change year over year.
  • BioMarin Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 214.07 M, a 143.44% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities